Loading clinical trials...
Loading clinical trials...
A Randomized Phase III Trial of Neoadjuvant Therapy in Patients With Palpable and Operable Breast Cancer Evaluating the Effect on Pathologic Complete Response (pCR) of Adding Capecitabine or Gemcitabine to Docetaxel When Administered Before AC With or Without Bevacizumab and Correlative Science Studies Attempting to Identify Predictors of High Likelihood for pCR With Each of the Regimens
Conditions
Interventions
bevacizumab
capecitabine
+4 more
Locations
442
United States
Arkansas Cancer Research Center at University of Arkansas for Medical Sciences
Little Rock, Arkansas, United States
East Bay Radiation Oncology Center
Castro Valley, California, United States
Eden Medical Center
Castro Valley, California, United States
Valley Medical Oncology Consultants - Castro Valley
Castro Valley, California, United States
Kaiser Permanente - Fremont
Fremont, California, United States
Valley Medical Oncology
Fremont, California, United States
Start Date
November 1, 2006
Primary Completion Date
March 1, 2011
Completion Date
March 1, 2018
Last Updated
September 18, 2017
NCT05468034
NCT04541381
NCT03137095
NCT07547774
NCT07040891
NCT06393374
Lead Sponsor
NSABP Foundation Inc
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions